-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
Dr. Mariano Provencio said the results could potentially define a standard adjuvant treatment for patients with resectable ES-NSCLC; however, longer-term observation is needed.
More News from #WCLC25
-
Test Your Knowledge at the Closing Lunch of the 2025 World Conference on Lung Cancer
Before you depart Barcelona, join your colleagues for lunch and an entertaining trivia competition, hosted by quizmaster Stephen Liu, MD.
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
Dr. David Planchard said the findings support a combination approach as a first-line treatment with an extended overall survival advantage for patients with EGFRm advanced NSCLC.